Syndax Pharmaceuticals Inc.
SNDXHeld by 10 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying10 funds opened new positions. Next phase2 readout (Axatilimab): Apr 2023. Short interest: 26.1% of float.
Held by 10 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying10 funds opened new positions. Next phase2 readout (Axatilimab): Apr 2023. Short interest: 26.1% of float.
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)
10 specialist funds hold SNDX with a Phase 2 in 33 days for Axatilimab (Idiopathic Pulmonary Fibrosis)
+2 more upcoming catalysts
Position history (shares)
Eventide Exit — SNDX
Eventide has fully exited Syndax, removing a values-aligned institutional holder from the cap table despite a crowded specialist roster of 10 funds still holding the name, including Cormorant, OrbiMed, and Deerfield. The exit is notable given the pending Phase 2 readout for axatilimab in IPF (Sept 2026) and the longer-dated Phase 3 revumenib AML readout (mid-2029), suggesting Eventide's conviction on risk/reward or timeline did not hold relative to opportunity cost.
8 quarters
Feb 17, 2026
$0
0 funds
Mar 16, 2026
$0
0 funds
May 15, 2026
$110.8M
2 funds
Aug 14, 2026
$116.3M
2 funds
+530% total institutional value over 23 quarters
Short Shares
22.90M
Change
+10.0%
Days to Cover
15.8
% of Float
26.1%
Settlement
Aug 14, 2026
Short interest over 12 periods
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.
# Summary for SNDX Investors This case report describes successful salvage therapy with revumenib (a KMT2A inhibitor) in a patient with isolated leukemia cutis, demonstrating potential clinical utility in extramedullary disease where standard therapies fail. The finding is notable because it suggests revumenib may address an underserved patient population with KMT2A-rearranged acute leukemias presenting with cutaneous manifestations, potentially expanding the addressable market beyond primary hematologic indications. However, this represents a single case study rather than systematic evidence; investors should await prospective data on revumenib's efficacy in extramedullary disease to assess meaningful commercial impact on SNDX's marketed or pipeline assets.
# Investment Summary: Syndax Pharmaceuticals (SNDX) **Clinical Finding:** The all-oral triplet combination of revumenib (SNDX-5613, Syndax's menin inhibitor), decitabine, and venetoclax demonstrated efficacy in relapsed/refractory AML, with potential to address a high-mortality patient population where treatment options are limited. **Commercial Implication:** If data supports favorable safety/efficacy profiles and regulatory approval, this combination could establish revumenib as a cornerstone agent in relapsed/refractory AML, expanding addressable market beyond monotherapy and potentially capturing combination therapy revenue streams alongside established agents (decitabine, venetoclax). **Investor Relevance:** Success here validates revumenib's clinical utility and strengthens Syndax's pipeline valuation; however, outcomes will depend on complete response rates, durability, and safety
# Investment Summary: SNDX Revumenib Case Report This case report documents clinical efficacy of revumenib (SNDX-5613), Syndax's menin inhibitor, in treating lineage switch infant leukemia—a rare but aggressive pediatric malignancy with limited treatment options. The successful response followed by hematopoietic cell transplantation demonstrates revumenib's potential utility in high-risk pediatric leukemia populations, though the case-report nature limits generalizability to broader commercial applicability. For investors, this adds clinical evidence supporting revumenib's label expansion potential in pediatric hematologic malignancies beyond the current approved adult KMT2r-rearranged acute leukemia indication, though regulatory pathway and market size for this rare pediatric subset remain uncertain.
# Investment Summary: SNDX Cardiac Safety Signal This case report documents severe cardiac toxicity (QTc prolongation and torsades de pointes) associated with revumenib, Syndax's lead menin inhibitor program currently in clinical development for acute leukemias. The adverse event raises potential cardiac safety concerns that could complicate the clinical development pathway, require additional monitoring protocols, or trigger additional cardiac studies that extend timelines and increase development costs. Investors should monitor regulatory feedback and upcoming trial data for the frequency and severity of cardiac events, as this safety profile could impact market positioning relative to competing menin inhibitors and the ultimate commercial viability of the program.
# Syndax Pharmaceuticals (SNDX) Investment Summary **Clinical Finding:** This case report documents efficacy of revumenib (a KMT2A inhibitor) combined with venetoclax and azacitidine in treating relapsed KMT2A-rearranged AML with CNS involvement, a typically fatal presentation with limited treatment options. **Investment Implications:** The case strengthens revumenib's clinical positioning in a high-unmet-need subset of AML patients, though single case reports have limited regulatory weight; broader clinical validation through ongoing trials will be critical to assess whether combination therapy can materially expand the commercial addressable market beyond monotherapy indications. **Key Consideration:** Investors should monitor Phase 2/3 trial data and competitive positioning versus other KMT2A-targeted approaches, as CNS penetration and combination regimen safety/efficacy data will determine the drug's
Start free trialfor share counts, dollar values & AI analysis
108 more position changes — start your free trial to see dollar values and AI analysis for all of them.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free TrialGet free weekly alerts on fund moves and catalysts: